Company intelligence / Profile preview

Inoviem Scientific

Strasbourg / Illkirch-Graffenstaden, Grand Est / Alsace / Bas-Rhin region, Franceinoviem.com ↗

Ownership: Private
Development stage: Commercial

Overview

Inoviem Scientific provides proprietary label-free platforms to analyze drug-target interactions, identify biomarkers, stratify patients, and optimize preclinical/clinical development. The company supports pharma/biotech clients but does not develop its own therapeutics. Its patented work includes safer hydroxychloroquine analogues for autoimmune/rare diseases. No direct clinical results reported as it operates as a service provider.

Therapeutic areas: OtherRare DiseasesImmunology
Modalities: Small moleculeMonoclonal antibodyProteomics-based analysisLabel-free drug profiling technologies
Industry: Contract Research Organization

Partnerships

Not specifically disclosed; works with "big pharma" and biotechs broadly as clients.

Beyond the preview

Go deeper on Inoviem Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inoviem Scientific.

Explore the full profile